[Featured Stock] NatureCell Soars 65% in 3 Consecutive Days as FDA RMAT Designation Ignites 'Fire Pillar'

Three Consecutive Days of Increase Starting from the 23rd, Total Growth Rate Reaches 65%
Rapid Development and Approval Expected with FDA's RMAT Designation
Jointstem Likely to Accelerate Entry into the US Market

Naturecell's stock price broke through its 52-week high for the first time in four months and surpassed the 15,000 KRW barrier. The stock continues to show strength following the U.S. Food and Drug Administration (FDA)'s designation of its advanced regenerative medicine therapy (RMAT).

As of 9:27 AM on the 25th, Naturecell is trading at 15,080 KRW, up 7.87% (1,100 KRW) from the previous trading day. Following a 24.42% increase on the 23rd and a 23.61% rise on the 24th, the stock reached an intraday high of 14,290 KRW, surpassing the 52-week high of 13,420 KRW recorded in June. On the 25th, it continues to climb with nearly a 10% increase, marking three consecutive days of strong gains. Since the 23rd, the stock has risen approximately 65%.

On the 23rd, Naturecell's 'Jointstem' was designated as an FDA RMAT. RMAT is a program introduced by the FDA in the field of regenerative medicine to expedite the development and approval process of therapies. It allows clinical trials and approval procedures to proceed at a faster pace than usual and provides various forms of FDA support.

'Jointstem' is a stem cell-based therapy developed for patients with severe degenerative arthritis. It has completed three clinical trials in South Korea. Having sufficiently verified its safety, Jointstem has gained momentum with the RMAT designation. It is expected to achieve success in the regenerative medicine therapy market through future entry into the U.S. market. The key factor will be the progress of clinical trials in the U.S. The timing of market entry depends on the speed of the FDA's clinical procedures and approval.

This content was produced with the assistance of AI translation services.